プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Shipra R.に依頼

United States

Scientific and Medical Strategy | Dermatology, Immunology, Cancer Biology | Translating Science into Market Success

プロフィール概要

CORE COMPETENCIES Pharmaceutical & Biotech Consulting: Strategic guidance from early-stage R&D to commercialization. Medical Affairs & Market Access: Bridging clinical evidence with real-world market needs. Clinical Study Design & Data Analysis: Expertise in designing and analyzing clinical trials. Product Development & Formulation: Specialized in dermatological, regenerative, and aesthetic medicine innovations. Scientific Writing & Publications: Authoring research articles, white papers, and regulatory submissions. Regulatory & Compliance Strategy: Ensuring adherence to global pharmaceutical regulations. INDUSTRIES & EXPERTISE Dermatology & Aesthetics: Biologics, Rx, OTC, and medical devices. Immunology & Inflammation: Cytokine therapies, secretome-based treatments, and regenerative medicine. Medical Devices & Biologics: Formulation, sustained-release technologies, and microneedle applications. Microbiome & Gut Health: Evidence-based ingredient selection and product evaluation. Men’s & Women’s Health: Focus on hormone-related dermatology, perimenopause, and aging. SERVICES OVERVIEW Scientific and medical consulting for pharmaceutical, biotech, and aesthetics companies. Clinical study design, execution, and data analysis. Regulatory strategy and compliance for global markets. Market access and competitive intelligence assessments. Strategic publication planning and manuscript development. Business development and licensing opportunities for novel technologies ACCOMPLISHMENTS 20+ years of experience in Pharma and Biotech in R&D and Medical Affairs. Expertise in the development and execution of medical and scientific strategy, launch preparation, and medical communications. Strategic advisor to three start-ups/early-stage biotech companies facilitated successful licensing deals with industry giants 3 Drug Launches including biologics 70 Peer Reviewed research articles, several publications, and 6 Patents 7 successful grant proposals https://www.linkedin.com/in/srastogi/ https://scholar.google.com/citations?user=F2x2LLkAAAAJ&hl=en

専門分野

• ★ Cell Biology
• ★ Dermatology
• ★ Medical Writing
• ☆ Cell Signaling Pathways
• ☆ Cell Culture
• ☆ Primary Cells
• ☆ Cell Surface Receptors
• ☆ 3D Cell Culture
• ☆ Cell Aging
• ☆ Drug Discovery
• ☆ Drug Target Identification
• ☆ Pharmacovigilance/Drug Safety Monitoring
• ☆ Clinical Immunology
• ☆ Skin Cancer
• ☆ Preventive Medicine
• ☆ Precision Medicine
• ☆ Plastic Surgery
• ☆ Cardiovascular Disease
• ☆ Cardiovascular Disease Management
• ☆ Medical Toxicology
• ☆ Healthcare Administration & Management
• ☆ Medical Affairs
• ☆ Traditional Medicine
• ☆ Photodermatology
• ☆ Dermatitis
• ☆ Medical Terminology
• ☆ Medical Sciences
• ☆ Cancer Research
• ☆ Cancer Biology
• ☆ Pharmaceutical Management
• ☆ Pharmaceutical Technology
• ☆ Product Evaluation
• ☆ Hypothesis
• ☆ Peer Review
• ☆ Research Methodology
• ☆ Survey Design & Methodology
• ☆ Fact Checking
• ☆ Literature Search
• ☆ Gap Analysis
• ☆ Gray Literature Search
• ☆ Medical Content Writing
• ☆ Continuing Medical Education (CME) Materials
• ☆ Healthcare Communications
• ☆ Patient Education Materials
• ☆ Research Summaries & Abstracts
• ☆ Medical Copywriting
• ☆ Technical & Scientific Writing
• ☆ Journal Selection
• ☆ Manuscript & Journal Article Writing
• ☆ Experimental Protocols
• ☆ SOP & Protocol Writing
• ☆ White Papers
• ☆ Textbook Content Writing
• ☆ Science Communication
• ☆ Traditional/Narrative Literature Review
• ☆ Scientific Proofreading & Editing
• ☆ Proofreading & Editing
• ☆ Language Translation
• ☆ Creative Writing
• ☆ Audio Transcription
• ☆ Course Content Writing
• ☆ Grant Writing
• ☆ Cosmetic & Skincare Formulation
• ☆ Hair Care Product Formulation
• ☆ Personal Care Product Formulation

サービス

• Writing
• Research
• Consulting
• Product Development

Writing Clinical Trial Documentation, Medical Writing, Non-Medical Regulatory Writing, Technical Writing, Business & Legal Writing, General Proofreading & Editing

Research Feasibility Study, Technology Scouting, Fact Checking, Gap Analysis, Gray Literature Search, Scientific and Technical Research, Secondary Data Collection

Consulting Business Strategy Consulting, Go-to-Market Strategy Consulting, Healthcare Consulting, Scientific and Technical Consulting

Product Development Product Compliance , Concept Development, Product Launch Support

職務経験

Medical Affairs Director

Galderma

5月 2022 - 7月 2023

Senior Director

Bausch Health

1月 2014 - 4月 2022

学歴

MBA

Richard Ivey School of Business, UWO

8月 2007 - 8月 2008

PhD

University of South Florida

7月 1997 - 7月 2003

認定資格

• 認定資格の詳細は未入力です。

出版物

JOURNAL ARTICLE

Langley, R.G., Armstrong, A.W., Lebwohl, M.G., Blauvelt, A., Hsu, S., Tyring, S., Rastogi, S., Pillai, R., Israel, R.(2019). Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials . British Journal of Dermatology. 180. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 306-314.

McMichael, A., Desai, S.R., Qureshi, A., Rastogi, S., Alexis, A.F.(2019). Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials . American Journal of Clinical Dermatology. 20. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 267-276.

Wu, J.J., Feldman, S.R., Rastogi, S., Menges, B., Lingohr-Smith, M., Lin, J.(2018). Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States . Journal of Dermatological Treatment. 29. (8). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 769-774.

Feldman, S.R., Rastogi, S., Lin, J.(2018). Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States . Dermatology and Therapy. 8. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 441-453.

Papp, K.A., Gordon, K.B., Langley, R.G., Lebwohl, M.G., Gottlieb, A.B., Rastogi, S., Pillai, R., Israel, R.J.(2018). Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3 . British Journal of Dermatology. 179. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 320-328.

Gottlieb, A.B., Gordon, K., Hsu, S., Elewski, B., Eichenfield, L.F., Kircik, L., Rastogi, S., Pillai, R., Israel, R.(2018). Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials . Journal of the European Academy of Dermatology and Venereology. 32. (8). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1305-1313.

Feldman, S.R., Wu, J.J., Rastogi, S., Menges, B., Lingohr-Smith, M., Lin, J.(2018). The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans . Journal of Medical Economics. 21. (5). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 537-541.

Lebwohl, M.G., Papp, K.A., Marangell, L.B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J.J., Rastogi, S., Harris, S., Pillai, R., et al.(2018). Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials . Journal of the American Academy of Dermatology. 78. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 81-89.e5.

Blauvelt, A., Papp, K.A., Lebwohl, M.G., Green, L.J., Hsu, S., Bhatt, V., Rastogi, S., Pillai, R., Israel, R.(2017). Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3) . Journal of the American Academy of Dermatology. 77. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 372-374.

Nikolis, A., Bernstein, S., Kinney, B., Scuderi, N., Rastogi, S., Sampalis, J.S.(2016). A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light on facial rejuvenation . Clinical, Cosmetic and Investigational Dermatology. 9. Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 115-125.

Rastogi, S., Rizwani, W., Joshi, B., Kunigal, S., Chellappan, S.P.(2012). TNF-α response of vascular endothelial and vascular smooth muscle cells involve differential utilization of ASK1 kinase and p73 . Cell Death and Differentiation. 19. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 274-283.

Dasgupta, P., Rizwani, W., Pillai, S., Kinkade, R., Kovacs, M., Rastogi, S., Banerjee, S., Carless, M., Kim, E., Coppola, D., et al.(2009). Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines . International Journal of Cancer. 124. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 36-45.

Rastogi, S., Banerjee, S., Chellappan, S., Simon, G.R.(2007). Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines . Cancer Letters. 257. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 244-251.

Timoshenko, A.V., Rastogi, S., Lala, P.K.(2007). Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells . British Journal of Cancer. 97. (8). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1090-1098.

Rastogi, S., Shukla, Y., Paul, B.N., Chowdhuri, D.K., Khanna, S.K., Das, M.(2007). Protective effect of Ocimum sanctum on 3-methylcholanthrene, 7,12-dimethylbenz(a)anthracene and aflatoxin B1 induced skin tumorigenesis in mice . Toxicology and Applied Pharmacology. 224. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 228-240.

Joshi, B., Rastogi, S., Morris, M., Carastro, L.M., DeCook, C., Seto, E., Chellappan, S.P.(2007). Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites . Biochemical Journal. 401. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 155-166.

Dasgupta, P., Rastogi, S., Pillai, S., Ordonez-Ercan, D., Morris, M., Haura, E., Chellappan, S.(2006). Erratum: Nicotine induces cell proliferation by β-arrestin-mediated activation of Src and Rb-Raf-1 pathways (Journal of Clinical Investigation (2006) 116, (2208-2217) DOI: 10.1172/JCI28164) . Journal of Clinical Investigation. 116. (11). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 3083.

Dasgupta, P., Rastogi, S., Pillai, S., Ordonez-Ercan, D., Morris, M., Haura, E., Chellappan, S.(2006). Nicotine induces cell proliferation by β-arrestin-mediated activation of Src and Rb-Raf-1 pathways . Journal of Clinical Investigation. 116. (8). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2208-2217.

Rastogi, S., Joshi, B., Dasgupta, P., Morris, M., Wright, K., Chellappan, S.(2006). Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes . Molecular and Cellular Biology. 26. (11). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 4161-4171.

Rastogi, S., Dogra, R.K.S., Khanna, S.K., Das, M.(2006). Skin tumorigenic potential of aflatoxin B1 in mice . Food and Chemical Toxicology. 44. (5). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 670-677.

Rastogi, S., Joshi, B., Fusaro, G., Chellappan, S.(2006). Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism . Journal of Biological Chemistry. 281. (5). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2951-2959.

Niesen, M.I., Osborne, A.R., Yang, H., Rastogi, S., Chellappan, S., Cheng, J.Q., Boss, J.M., Blanck, G.(2005). Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX . Journal of Biological Chemistry. 280. (47). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 38914-38922.

Rastogi, S., Dwivedi, P.D., Khanna, S.K., Das, M.(2004). Detection of Aflatoxin M1 contamination in milk and infant milk products from Indian markets by ELISA . Food Control. 15. (4). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 287-290.

Dasgupta, P., Betts, V., Rastogi, S., Joshi, B., Morris, M., Brennan, B., Ordonez-Ercan, D., Chellappan, S.(2004). Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein: Novel links between apoptotic signaling and cell cycle machinery . Journal of Biological Chemistry. 279. (37). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 38762-38769.

Das, M., Rastogi, S., Khanna, S.K.(2004). Mechanism to study 1:1 stoichiometry of NADPH and alkoxyphenoxazones metabolism spectrophotometrically in subcellular biological preparations . Biochimica et Biophysica Acta - General Subjects. 1675. (1-3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1-11.

Fusaro, G., Dasgupta, P., Rastogi, S., Joshi, B., Chellappan, S.(2003). Prohibitin Induces the Transcriptional Activity of p53 and Is Exported from the Nucleus upon Apoptotic Signaling . Journal of Biological Chemistry. 278. (48). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 47853-47861.

Rastogi, S., Khanna, S.K., Das, M.(2002). A spectrophotometric method to monitor the catalytic activity of microsomal cytochrome P-450 IIB 1/2: Comparison with fluorometric assay . Indian Journal of Biochemistry and Biophysics. 39. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 191-196.

Rastogi, S., Das, M., Khanna, S.K.(2002). A novel approach to study the activity and stoichiometry simultaneously for microsomal pentoxyresorufin-O-dealkylase reaction . FEBS Letters. 512. (1-3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 121-124.

Rastogi, S., Das, M., Khanna, S.K.(2001). Quantitative determination of aflatoxin B1-oxime by column liquid chromatography with ultraviolet detection . Journal of Chromatography A. 933. (1-2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 91-97.